219 related articles for article (PubMed ID: 16451281)
1. Rasagiline -- is there a place for this drug in managing Parkinson's disease?
Sharma JC
Int J Clin Pract; 2006 Feb; 60(2):132-3. PubMed ID: 16451281
[No Abstract] [Full Text] [Related]
2. Rasagiline as a therapy for Parkinson's disease (PD).
Hermanowicz N
Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
[No Abstract] [Full Text] [Related]
3. Rasagiline. Parkinson's disease: a simple me-too.
Prescrire Int; 2006 Dec; 15(86):220. PubMed ID: 17167927
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
5. [Rasagiline in motor fluctuations].
Miletzki A
Fortschr Neurol Psychiatr; 2005 Sep; 73(9):488. PubMed ID: 16217881
[No Abstract] [Full Text] [Related]
6. New drug treatment for Parkinson's disease.
FDA Consum; 2006; 40(4):7. PubMed ID: 17245831
[No Abstract] [Full Text] [Related]
7. [Rasagiline: effectiveness and protection in Parkinson's disease].
Pagonabarraga J; Kulisevsky J
Rev Neurol; 2010 Nov; 51(9):535-41. PubMed ID: 20979033
[TBL] [Abstract][Full Text] [Related]
8. Rasagiline in Parkinson's disease.
Chahine LM; Stern MB
Int Rev Neurobiol; 2011; 100():151-68. PubMed ID: 21971007
[TBL] [Abstract][Full Text] [Related]
9. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
10. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease.
Stocchi F
Int J Clin Pract; 2006 Feb; 60(2):215-21. PubMed ID: 16451296
[TBL] [Abstract][Full Text] [Related]
11. Rasagiline. Teva Pharmaceutical.
Kupsch A
Curr Opin Investig Drugs; 2002 May; 3(5):794-7. PubMed ID: 12090555
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
Mandel S; Weinreb O; Amit T; Youdim MB
Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
[TBL] [Abstract][Full Text] [Related]
13. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
15. Rasagiline (Azilect) for Parkinson's disease.
Med Lett Drugs Ther; 2006 Dec; 48(1249/1250):97-9. PubMed ID: 17149358
[No Abstract] [Full Text] [Related]
16. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
Chen JJ; Swope DM
J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
[TBL] [Abstract][Full Text] [Related]
17. [Rasagiline in Parkinson's disease].
Linazasoro G
Neurologia; 2008 May; 23(4):238-45. PubMed ID: 18307054
[TBL] [Abstract][Full Text] [Related]
18. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
Naoi M; Maruyama W
Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610
[TBL] [Abstract][Full Text] [Related]
19. [The early therapy challenge].
Reichmann H
Krankenpfl J; 2005; 43(7-10):240. PubMed ID: 16515310
[No Abstract] [Full Text] [Related]
20. Rasagiline in Parkinson's disease.
Schwarzschild MA
N Engl J Med; 2010 Feb; 362(7):658; author reply 658-9. PubMed ID: 20187261
[No Abstract] [Full Text] [Related]
[Next] [New Search]
